Neil CPA - Compass Therapeutics Vice Finance

CMPX Stock  USD 1.31  0.02  1.55%   

Executive

Neil CPA is Vice Finance of Compass Therapeutics
Age 57
Address 80 Guest Street, Boston, MA, United States, 02135
Phone(617) 500-8099
Webhttps://www.compasstherapeutics.com

Compass Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1913) % which means that it has lost $0.1913 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2735) %, meaning that it created substantial loss on money invested by shareholders. Compass Therapeutics' management efficiency ratios could be used to measure how well Compass Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.35 in 2024. At this time, Compass Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 3.5 M in 2024, whereas Total Assets are likely to drop slightly above 120.5 M in 2024.
Compass Therapeutics currently holds 1.73 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Compass Therapeutics has a current ratio of 12.11, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Compass Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

EXECUTIVE Age

Elly MDDay One Biopharmaceuticals
N/A
Adam DubowDay One Biopharmaceuticals
57
Lauren MBADay One Biopharmaceuticals
48
Prof MDDay One Biopharmaceuticals
55
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. Compass Therapeutics (CMPX) is traded on NASDAQ Exchange in USA. It is located in 80 Guest Street, Boston, MA, United States, 02135 and employs 32 people. Compass Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Compass Therapeutics Leadership Team

Elected by the shareholders, the Compass Therapeutics' board of directors comprises two types of representatives: Compass Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compass. The board's role is to monitor Compass Therapeutics' management team and ensure that shareholders' interests are well served. Compass Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compass Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Susan Kalled, Chief Officer
Jonathan JD, Head VP
MD MBA, Chief Officer
Neil CPA, Vice Finance
Peter Moesta, Interim CMC
Anna Gifford, Communications Manager
Karin BA, VP Operations
Vered MBA, Pres COO
Minori MD, Senior Development
James Kranz, VP Controls

Compass Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compass Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.